{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:39:23Z","timestamp":1715974763339},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10928-014-9362-4","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T10:43:43Z","timestamp":1403174623000},"page":"261-278","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator"],"prefix":"10.1007","volume":"41","author":[{"given":"Andreas","family":"Krause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Brossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,15]]},"reference":[{"issue":"2","key":"9362_CR1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","volume":"337","author":"L Piali","year":"2011","unstructured":"Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E, Kohl C, Steiner B, Clozel M (2011) The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337(2):547\u2013556. doi: 10.1124\/jpet.110.176487","journal-title":"J Pharmacol Exp Ther"},{"issue":"S1","key":"9362_CR2","first-page":"S56","volume":"87","author":"P Brossard","year":"2010","unstructured":"Brossard P, D\u2019Ambrosio D, Cavallaro M, Dingemanse J (2010) Differential effects of ACT-128800, a selective S1P1 receptor agonist, on blood-circulating human T-lymphocyte subpopulations. Poster presented at the 111th Am Soc Clin Pharmacol Ther (ASCPT) meeting, Atlanta, GA, 17\u201320 March, 2010 Poster PIII-82. Clin Pharmacol Ther 87(S1):S56","journal-title":"Clin Pharmacol Ther"},{"issue":"6972","key":"9362_CR3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355\u2013360. doi: 10.1038\/nature02284","journal-title":"Nature"},{"issue":"5741","key":"9362_CR4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1126\/science.1113640","volume":"309","author":"SR Schwab","year":"2005","unstructured":"Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741):1735\u20131739. doi: 10.1126\/science.1113640","journal-title":"Science"},{"issue":"6","key":"9362_CR5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","volume":"76","author":"P Brossard","year":"2013","unstructured":"Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J (2013) Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76(6):888\u2013896. doi: 10.1111\/bcp.12129","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9362_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jcph.244","volume":"54","author":"P Brossard","year":"2014","unstructured":"Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J (2014) Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 54(2):179\u2013188. doi: 10.1002\/jcph.244","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9362_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00228-013-1625-2","volume":"70","author":"M Reyes","year":"2014","unstructured":"Reyes M, Brossard P, Chassard D, Hoch M, Dingemanse J (2014) Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70(3):287\u2013293. doi: 10.1007\/s00228-013-1625-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"S1","key":"9362_CR8","first-page":"S92","volume":"91","author":"P Brossard","year":"2012","unstructured":"Brossard P, D\u2019Ambrosio D, Murat I, Dingemanse J (2012) Effects of three different up-titration regimens of ponesimod, a selective S1P1 receptor agonist, on heart rate. Poster presented at the 113th Am Soc Clin Pharmacol Ther (ASCPT) Meeting, National Harbor, MD, 14\u201317 March, 2012 Poster PII-109. Clin Pharmacol Ther 91(S1):S92\u2013S93","journal-title":"Clin Pharmacol Ther"},{"key":"9362_CR9","unstructured":"Vaclavkova A, Brossard P, Cavallaro M, D\u2019Ambrosio D, Nacarino Martinez A, Morganti A, Pirron U, Schmidt A-G, Zhang-Fu W (2011) AC-058A200: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6\u00a0weeks to subjects with moderate to severe chronic plaque psoriasis. Pubmed. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00852670"},{"key":"9362_CR10","unstructured":"Holford NH Absorption models using NM-TRAN. http:\/\/holford.fmhs.auckland.ac.nz\/docs\/absorption-processes.pdf"},{"issue":"5","key":"9362_CR11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01061464","volume":"20","author":"NH Holford","year":"1992","unstructured":"Holford NH, Ambros RJ, Stoeckel K (1992) Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 20(5):421\u2013442","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"9362_CR12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jclinpath-2013-201776","volume":"66","author":"S Braude","year":"2013","unstructured":"Braude S, Beck A (2013) Complete blood counts with differential: more accurate reference ranges based on circadian leukocyte trafficking. J Clin Pathol 66(11):909\u2013910. doi: 10.1136\/jclinpath-2013-201776","journal-title":"J Clin Pathol"},{"issue":"6","key":"9362_CR13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10875-012-9730-z","volume":"32","author":"S Kirsch","year":"2012","unstructured":"Kirsch S, Thijssen S, Alarcon Salvador S, Heine GH, van Bentum K, Fliser D, Sester M, Sester U (2012) T-cell numbers and antigen-specific T-cell function follow different circadian rhythms. J Clin Immunol 32(6):1381\u20131389. doi: 10.1007\/s10875-012-9730-z","journal-title":"J Clin Immunol"},{"issue":"4","key":"9362_CR14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01062461","volume":"20","author":"LE Fisher","year":"1992","unstructured":"Fisher LE, Ludwig EA, Jusko WJ (1992) Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm 20(4):319\u2013331","journal-title":"J Pharmacokinet Biopharm"},{"key":"9362_CR15","unstructured":"Holford NH (2012) An introduction to visual predictive checks. http:\/\/holford.fmhs.auckland.ac.nz\/docs\/vpc-tutorial-and-datatop.pdf"},{"key":"9362_CR16","unstructured":"Karlsson MO (2008) A tutorial on visual predictive checks. http:\/\/www.page-meeting.org\/?abstract=1434"},{"key":"9362_CR17","unstructured":"SAS Institute Inc. (2006) Base SAS 9.1.3 procedures guide. SAS Institute Inc., Cary"},{"key":"9362_CR18","unstructured":"R Development Core Team (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"9362_CR19","unstructured":"Beal SL, Sheiner LB (1989\u20131998) NONMEM users guides. Icon Development Solutions, Ellicott City"},{"key":"9362_CR20","unstructured":"Free Software Foundation (2009) GNU Fortran. http:\/\/gcc.gnu.org\/fortran\/"},{"key":"9362_CR21","unstructured":"Metrum Institute (2008) NMQual: A software environment for operating NONMEM. https:\/\/code.google.com\/p\/nmqual\/"},{"issue":"3","key":"9362_CR22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569. doi: 10.1208\/s12248-009-9133-0","journal-title":"AAPS J"},{"issue":"8S","key":"9362_CR23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.clinthera.2013.07.014","volume":"35","author":"M Hoch","year":"2013","unstructured":"Hoch M, D\u2019Ambrosio D, Wilbraham D, Dingemanse J (2013) Up-titration study with ponesimod, a selective S1P1 receptor modulator, to assess its maximum tolerated dose in healthy subjects. Oral contribution OC015 presented at the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Geneva, Switzerland, August 28\u201331, 2013. Clin Ther 35(8S):e6\u2013e7","journal-title":"Clin Ther"},{"issue":"4","key":"9362_CR24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","volume":"20","author":"G Francis","year":"2013","unstructured":"Francis G, Kappos L, O\u2019Connor P, Collins W, Tang D, Mercier F, Cohen J (2013) Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 20(4):471\u2013480. doi: 10.1177\/1352458513500551","journal-title":"Mult Scler"},{"issue":"8 Suppl 3","key":"9362_CR25","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.0b013e31820db341","volume":"76","author":"M Mehling","year":"2011","unstructured":"Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A (2011) Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76(8 Suppl 3):S20\u2013S27. doi: 10.1212\/WNL.0b013e31820db341","journal-title":"Neurology"},{"issue":"Suppl 1","key":"9362_CR26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.0b013e3181c97c8f","volume":"74","author":"LH Kasper","year":"2010","unstructured":"Kasper LH, Shoemaker J (2010) Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74(Suppl 1):S2\u2013S8. doi: 10.1212\/WNL.0b013e3181c97c8f","journal-title":"Neurology"},{"issue":"5","key":"9362_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrom E (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167(5):1035\u20131047. doi: 10.1111\/j.1476-5381.2012.02061.x","journal-title":"Br J Pharmacol"},{"issue":"16","key":"9362_CR28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","volume":"71","author":"M Mehling","year":"2008","unstructured":"Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71(16):1261\u20131267. doi: 10.1212\/01.wnl.0000327609.57688.ea","journal-title":"Neurology"},{"issue":"20","key":"9362_CR29","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/01.wnl.0000435564.92609.2c","volume":"81","author":"D Henault","year":"2013","unstructured":"Henault D, Galleguillos L, Moore C, Johnson T, Bar-Or A, Antel J (2013) Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology 81(20):1768\u20131772. doi: 10.1212\/01.wnl.0000435564.92609.2c","journal-title":"Neurology"},{"issue":"8S","key":"9362_CR30","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/j.clinthera.2013.07.201","volume":"35","author":"M Hoch","year":"2013","unstructured":"Hoch M, Vaclavkova A, Stoltz R, Brossard P, Dingemanse J (2013) Thorough QT study with ponesimod, a selective S1P1 receptor modulator. Poster PP162 presented at the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Geneva, Switzerland, August 28\u201331, 2013. Clin Ther 35(8S):e68\u2013e69","journal-title":"Clin Ther"},{"key":"9362_CR31","doi-asserted-by":"crossref","unstructured":"Vaclavkova A, Chimenti S, Arenberger P, Holl\u00f3 P, Sator P-G, Burcklen M, Stefani M, D\u2019Ambrosio D (2014) A multicentre, randomised, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy, safety and tolerability of ponesimod, an oral sphingosine 1-phosphate receptor-1 modulator, in patients with chronic plaque psoriasis. Lancet (to appear)","DOI":"10.1016\/S0140-6736(14)60803-5"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-014-9362-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9362-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T09:04:06Z","timestamp":1559466246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-014-9362-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9362"],"URL":"https:\/\/doi.org\/10.1007\/s10928-014-9362-4","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}